FDA Clearance Tracker · P960007
TRANSCYTE HUMAN FIBROBLAST-DERIVED TEMPORARY SKIN SUBSTITUTE
Last checked: Nov 20, 2026Latest source record: Mar 18, 1997 (this decision)Source: openFDAMethods & limitations
Decided
Mar 18, 1997
Approved (conversion)
Time to decision
354 days
Received Mar 29, 1996. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P960007
- Device name
- TRANSCYTE HUMAN FIBROBLAST-DERIVED TEMPORARY SKIN SUBSTITUTE
- Applicant
- Shire Regenerative Medicine
- Applicant location
- San Diego, CA
- Received
- Mar 29, 1996
- Decided
- Mar 18, 1997
- Decision
- Approved (conversion)
- Supplements
- 19 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- Dressing, wound and burn, interactive (MGR)
- Device class
- Class III
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE DERMAGRAFT-TC(TM). THE DEVICE IS INDICATED FOR USE AS A TEMPORARY WOUND COVERING FOR SURGICALLY EXCISED FULL-THICKNESS AND DEEP PARTIAL-THICKNESS THERMAL BURN WOUNDS IN PATIENTS WHO REQUIRE SUCH A COVERING PRIOR TO AUTOGRAFT PLACEMENT
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MGR. The earliest in FDA's data is P900033, decided Mar 1, 1996.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Shire Regenerative Medicine
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.